In the Specification:

Please replace the paragraph beginning at page 51, line 3, with the following:

--In certain embodiments, the T helper peptide is one that is recognized by T helper cells present in the majority of the population. This can be accomplished by selecting amino acid sequences that bind to many, most, or all of the HLA class II molecules. These are known as "loosely HLA-restricted" or "promiscuous" T helper sequences. Examples of amino acid sequences that are promiscuous include sequences from antigens such as tetanus toxoid at positions 830-843 (QYIKANSKFIGITE; SEQ ID NO:1487), *Plasmodium falciparum* CS protein at positions 378-398 (DIEKKIAKMEKASSVFNVVNS; SEQ ID NO:1488), and Streptococcus 18kD protein at positions 116 (GAVDSILGGVATYGAA; SEQ ID NO:1489). Other examples include peptides bearing a DR 1-4-7 supermotif, or either of the DR3 motifs.--

Please replace the paragraph beginning at page 51, line 12, with the following:

--Alternatively, it is possible to prepare synthetic peptides capable of stimulating T helper lymphocytes, in a loosely HLA-restricted fashion, using amino acid sequences not found in nature (*see, e.g.*, PCT publication WO 95/07707). These synthetic compounds called Pan-DR-binding epitopes (*e.g.*, PADRE™, Epimmune, Inc., San Diego, CA) are designed to most preferrably bind most HLA-DR (human HLA class II) molecules. For instance, a pan-DR-binding epitope peptide having the formula: aKXVWANTLKAAa (SEQ ID NO:1490), where "X" is either cyclohexylalanine, phenylalanine, or tyrosine, and "a" is either D-alanine or L-alanine, has been found to bind to most HLA-DR alleles, and to stimulate the response of T helper lymphocytes from most individuals, regardless of their HLA type. An alternative of a pan-DR binding

epitope comprises all "L" natural amino acids and can be provided in the form of nucleic

acids that encode the epitope.

Please replace the pages set forth below with the substitute pages attached hereto in Appendix A.

Please substitute page 100 (Table IV), the attached Substitute Sheet, page 100.

Please substitute page 101 (Table V) with the attached Substitute Sheet, page 101.

Please substitute pages 129-130 (Table XIX) with the attached Substitute Sheets, pages 129-130.

Please substitute pages 131-134 (Table XX) with the attached Substitute Sheets, pages 131-134.

Please substitute page 136 (Table XXII) with the attached Substitute Sheet, page 136.

Please substitute page 137 (Table XXII A) with the attached Substitute Sheet, page 137.

Please substitute page 138 (Table XXII B) with the attached Substitute Sheet, page 138.

Please substitute page 139 (Table XXII C) with the attached Substitute Sheet, page 139.

Please substitute page 140 (Table XXII D) with the attached Substitute Sheet, page 140.

Please substitute page 141 (Table XXII E) with the attached Substitute Sheet, page 141.

Please substitute page 142 (Table XXIII) attached Substitute Sheet, page 142.

Please substitute pages 143-144 (Table XXIV) with the attached Substitute Sheets pages 143-144.

Please substitute page 146 (Table XXVI) with the attached Substitute Sheet, page 146.

Please substitute page 147 (Table XXVII) with the attached Substitute Sheet, page 147.

Please substitute page 148 (Table XXVIII) with the attached Substitute Sheet, page 148.

Please substitute page 149 (Table XXIX) with the attached Substitute Sheet, page 149.

Please substitute page 150 (Table XXX) with the attached Substitute Sheet, page 150.

Please substitute page 151 (Table XXXI) with the attached Substitute Sheet, page 151.

Please substitute page 152 (Table XXXII) with the attached Substitute Sheet, page 152.

Please substitute page 153 (Table XXXIII) with the attached Substitute Sheet, page 153.